Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval for a clinical trial of their innovative drug, SKB500, aimed at treating advanced solid tumors. This novel ADC drug, developed using the OptiDC platform, has shown promising preclinical results. Investors are advised to exercise caution as the drug’s development and commercialization are not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.